New bispecific drug targets Hard-to-Treat cancers in early trial

NCT ID NCT06840119

Recruiting now Disease control Sponsor: Immunocore Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called IMC-R117C, alone or with other cancer drugs, in people with advanced colorectal, esophageal, stomach, or ovarian cancers that have a specific genetic marker (HLA-A*02:01) and produce a protein called PIWIL1. The trial aims to find safe doses and check if the drug can shrink tumors. About 600 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IMC-R117C (a bispecific protein that targets cancer cells and immune cells)
What this could lead to: If successful, this could lead to a new treatment option for certain advanced cancers that have not responded to standard therapies.
What could go wrong: This is an early first-in-human trial, so safety and effectiveness are not yet known. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer carcinoma of esophagus colorectal carcinoma gastric carcinoma neoplasm ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER HLA-A*02:01-POSITIVE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Antoni van Leeuwenhoek
RECRUITING

Amsterdam, Netherlands
Centro Integral Oncologico Clara Campal
RECRUITING

Madrid, Spain
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
RECRUITING

Roma, Italy
Hospital HM Nou Delfos
RECRUITING

Barcelona, Spain
Hospital Universitario Fundacion Jimenez Diaz
RECRUITING

Madrid, Spain
Institut Jules Bordet
RECRUITING

Anderlecht, 1070, Belgium
Peter MacCallum Cancer Centre
RECRUITING

Melbourne, Australia
St Vincent's Hospital
ACTIVE_NOT_RECRUITING

Darlinghurst, Sydney, NSW 2010, Australia
UZ Leuven
RECRUITING

Leuven, 3000, Belgium
Universitaetsklinikum Heidelberg
RECRUITING

Heidelberg, Germany
Universitair Ziekenhuis Gent
RECRUITING

Ghent, Belgium
VHIO, Vall d'Hebron University Hospital
RECRUITING

Barcelona, Spain
nstituto Clinico Humanitas
RECRUITING

Rozzano, 20089, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.